This update serves to clarify that Amersham has not sold its CodeLink business to EMBL, but rather a CodeLink system for internal research.


NEW YORK, Jan. 21 (GenomeWeb News) - Amersham Biosciences has sold a CodeLink microarray platform to the European Molecular Biology Laboratory, Amersham said today.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.